The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Positive Survival Data in Lung Cancer With Perioperative Therapy

2.

Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer

3.

Sickle Cell Disease Drug Pulled From Global Markets

4.

Biomarker panel offers hope for early pancreatic cancer detection

5.

Having dense breasts is linked to cancer, but advice about breast density can depend on where you live


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot